HEPAVEC AG
HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.
HEPAVEC AG
Industry:
Biotechnology Medical Therapeutics
Address:
Berlin, Berlin, Germany
Country:
Germany
Status:
Active
Contact:
+49 30 94892282
Total Funding:
5.9 M USD
Similar Organizations
BIRD-C
BIRD-C is a privately held R&D biotechnology company based in Vienna, Austria.
Genopoietic
Genopoietic is a privately held biotechnology company.
Kherion Technology
Kherion Technology is a privately held biotechnology company.
SomaGenics
SomaGenics is a privately held biotechnology company.
Stage Cell Therapeutics
Stage is a privately held biotech company active since 2005.
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 1999-11-08 | MondoGen | MondoGen acquired by HepaVec AG | N/A |
Investors List
DKA Capital
DKA Capital investment in Series A - HepaVec AG
Techno Venture Management
Techno Venture Management investment in Series A - HepaVec AG
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - HepaVec AG